Protein C News and Research

RSS

Integral Molecular releases MPS antibody discovery platform

ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.

23 Apr 2013

Research findings could provide a way to treat onset, progression of Parkinson's disease

The earliest signs of Parkinson's disease can be deceptively mild. The first thing that movie star Michael J. Fox noticed was twitching of the little finger of his left hand.

23 Apr 2013

Findings open new possibilities for research, testing treatments to combat obesity

Joslin scientists report significant findings about the location, genetic expression and function of human brown adipose tissue and the generation of new BAT cells.

23 Apr 2013

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

Researchers from Huntsman Cancer Institute at the University of Utah have developed a novel and powerful technique to identify the targets for a group of enzymes called RNA cytosine methyltransferases in human RNA.

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.

22 Apr 2013

Study provides medical chemists with tools to design safer drugs, predict their side effects

Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory paralysis. These are some of the 1,600 known side effects (SEs) produced by drugs.

22 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Advanced microscope reveals process where mutations lead to autism and other diseases

Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.

22 Apr 2013

3D image of cell signaling molecules indicates a trippable power switch

A three-dimensional image of one of the proteins that serves as an on-off switch as it binds to receptors on the surface of a cell suggests there may be a sort of main power switch that could be tripped. These surface receptors are responsible for helping cells discern light, set the heart racing, or detect pain.

22 Apr 2013

New application tool is a user-friendly alternative to previous dietary recall methods

A new website application for athletes called Dietary Analysis Tool for Athletes (D.A.T.A.) has been validated as accurately recording dietary intake based on the 24-hour recall method. "This tool offers sports dietitians and health professionals a new, quick alternative to analyze athletes' dietary intake," said Lindsay Baker, PhD, Principal Scientist, Gatorade Sports Science Institute.

22 Apr 2013

Edible malarial vaccine may work against other viral and bacterial infections

Can scientists rid malaria from the Third World by simply feeding algae genetically engineered with a vaccine? That's the question biologists at UC San Diego sought to answer after they demonstrated last May that algae can be engineered to produce a vaccine that blocks malaria transmission.

22 Apr 2013

Study highlights the protective effect of berries on brain function

Adding more color to your diet in the form of berries is encouraged by many nutrition experts. The protective effect of berries against inflammation has been documented in many studies.

22 Apr 2013

Researchers decipher the underlying mechanism of antiviral drug

A long-forgotten candidate for antiviral therapy is undergoing a renaissance: Since the 1970s, the small molecule CMA has been considered a potent agent against viral infections, yet it was never approved for clinical use.

22 Apr 2013

New chemical compound offers a promising step for creating potential anti-cancer agents

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.

22 Apr 2013

Potential therapies for smell loss

Snot. It's not something most of us spend a lot of time thinking about, but, for a team of researchers in Washington, D.C., it's front and center.

22 Apr 2013

Researchers find new potential target for anti-telomerase cancer therapy

Researchers at UT Southwestern Medical Center have found that alternative splicing - a process that allows a single gene to code for multiple proteins - appears to be a new potential target for anti-telomerase cancer therapy.

20 Apr 2013

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Shc plays key role in activating and controlling Erk

A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology.

20 Apr 2013

Protein C News and Research

Integral Molecular releases MPS antibody discovery platform

Research findings could provide a way to treat onset, progression of Parkinson's disease

Findings open new possibilities for research, testing treatments to combat obesity

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Discovery reverses the prevailing model of how dividing cells monitor equal distribution of chromosomes

Study provides medical chemists with tools to design safer drugs, predict their side effects

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Advanced microscope reveals process where mutations lead to autism and other diseases

3D image of cell signaling molecules indicates a trippable power switch

New application tool is a user-friendly alternative to previous dietary recall methods

Edible malarial vaccine may work against other viral and bacterial infections

Study highlights the protective effect of berries on brain function

Researchers decipher the underlying mechanism of antiviral drug

New chemical compound offers a promising step for creating potential anti-cancer agents

Potential therapies for smell loss

Researchers find new potential target for anti-telomerase cancer therapy

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Shc plays key role in activating and controlling Erk

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News